These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 25420483)

  • 1. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease.
    Ding J; Chen Q; Zhuang X; Feng Z; Xu L; Chen F
    Med Sci Monit; 2014 Nov; 20():2421-9. PubMed ID: 25420483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus.
    Singh S; Venketesh S; Verma JS; Verma M; Lellamma CO; Goel RC
    Indian J Med Res; 2007 Jun; 125(6):783-7. PubMed ID: 17704557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose.
    Lu C; Gao Y; Zhou H; Tian H
    Coron Artery Dis; 2008 Dec; 19(8):565-73. PubMed ID: 19005291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum paraoxonase1 activity levels predict coronary artery disease severity.
    Sun T; Hu J; Yin Z; Xu Z; Zhang L; Fan L; Zhuo Y; Wang C
    Oncotarget; 2017 Mar; 8(12):19443-19454. PubMed ID: 28038449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia.
    Fridman O; Gariglio L; Riviere S; Porcile R; Fuchs A; Potenzoni M
    Arch Cardiol Mex; 2016; 86(4):350-357. PubMed ID: 27640339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease.
    Kerkeni M; Addad F; Chauffert M; Chuniaud L; Miled A; Trivin F; Maaroufi K
    Clin Biochem; 2006 Aug; 39(8):821-5. PubMed ID: 16875684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients.
    Amine K; Atouk A; Moussamih S; Saile R; Mikou A; Kettani A
    Ann Biol Clin (Paris); 2011; 69(6):671-7. PubMed ID: 22123566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes.
    Sentürk T; Sarandöl E; Güllülü S; Erdinç S; Ozdemir B; Baran I; Aydinlar A
    Acta Cardiol; 2008 Jun; 63(3):361-7. PubMed ID: 18664028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus.
    Shen Y; Ding FH; Sun JT; Pu LJ; Zhang RY; Zhang Q; Chen QJ; Shen WF; Lu L
    Cardiovasc Diabetol; 2015 May; 14():52. PubMed ID: 25964115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase and arylesterase activities in coronary artery disease.
    Gur M; Aslan M; Yildiz A; Demirbag R; Yilmaz R; Selek S; Erel O; Ozdogru I
    Eur J Clin Invest; 2006 Nov; 36(11):779-87. PubMed ID: 17032345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease.
    Yunoki K; Naruko T; Inaba M; Inoue T; Nakagawa M; Sugioka K; Ohsawa M; Iwasa Y; Komatsu R; Itoh A; Haze K; Yoshiyama M; Becker AE; Ueda M
    Atherosclerosis; 2013 Dec; 231(2):308-14. PubMed ID: 24267244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
    Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
    Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
    Saeed SA; Elsharkawy M; Elsaeed K; Fooda O
    Hemodial Int; 2008 Oct; 12(4):471-9. PubMed ID: 19090870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women.
    Sutherland WH; Manning PJ; de Jong SA; Allum AR; Jones SD; Williams SM
    Metabolism; 2001 Mar; 50(3):319-24. PubMed ID: 11230785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
    Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
    Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraoxonase and arylesterase activities in stent restenosis in bare metal stent.
    Demirbag R; Sezen Y; Yeşilay AB; Bas M; Yildiz A; Guntekin U; Aksoy N
    Coron Artery Dis; 2011 Aug; 22(5):289-93. PubMed ID: 21394024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
    Bansal S; Chawla D; Siddarth M; Banerjee BD; Madhu SV; Tripathi AK
    Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative status and serum PON1 activity in beta-thalassemia minor.
    Selek S; Aslan M; Horoz M; Gur M; Erel O
    Clin Biochem; 2007 Mar; 40(5-6):287-91. PubMed ID: 17296173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease.
    Vaisi-Raygani A; Ghaneialvar H; Rahimi Z; Tavilani H; Pourmotabbed T; Shakiba E; Vaisi-Raygani A; Kiani A; Aminian M; Alibakhshi R; Bartels C
    Mol Biol Rep; 2011 Nov; 38(8):5421-8. PubMed ID: 21465165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia.
    Aslan M; Kosecik M; Horoz M; Selek S; Celik H; Erel O
    Atherosclerosis; 2007 Apr; 191(2):397-402. PubMed ID: 16684543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.